BridgeBio Oncology Therapeutics (BBOT) Cash from Financing Activities (2024 - 2026)
BridgeBio Oncology Therapeutics (BBOT) posted Cash from Financing Activities of $295000.0 for Q1 2026, up 150.34% sequentially from -$586000.0 in Q4 2025, and up 173.02% YoY from $108050.8 in Q1 2025.
BridgeBio Oncology Therapeutics (BBOT) Cash from Financing Activities (2024 - 2026) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Cash from Financing Activities for 3 years, with the latest figure at $295000.0 in Q1 2026.
- Quarterly Cash from Financing Activities rose 173.02% year-over-year to $295000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$643000.0 (down 103.31% YoY) and the FY2025 annual result came in at $383.4 million, up 85.86% from the prior year.
- Cash from Financing Activities grew to $295000.0 in Q1 2026 per BBOT's latest filing, from -$586000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $186.5 million in Q1 2024 and troughed at -$586000.0 in Q4 2025.
- A 3-year average of $34.3 million and a median of $173500.0 in 2024 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2025 and 2026: Cash from Financing Activities plunged 1226.92% in 2025, then jumped 173.02% in 2026.
- Over 3 years, Cash from Financing Activities stood at $52000.0 in 2024, then slumped by 1226.92% to -$586000.0 in 2025, then soared by 150.34% to $295000.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $295000.0, -$586000.0, and -$404000.0 for Q1 2026, Q4 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | BridgeBio Oncology Therapeutics | 726.38 Mn | 500.67 Mn | - | 37,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37,000.00 |
| Jun 30, 2026 | 37,000.00 |
| Mar 31, 2026 | 295,000.00 |
| Mar 31, 2026 | 295,000.00 |
| Dec 31, 2025 | -586,000.00 |
| Dec 31, 2025 | -586,000.00 |
| Mar 31, 2025 | -404,000.00 |
| Mar 31, 2025 | -404,000.00 |
| Dec 31, 2024 | 52,000.00 |
| Dec 31, 2024 | 52,000.00 |
| Sep 30, 2024 | 19.78 Mn |
| Sep 30, 2024 | 19.78 Mn |
| Mar 31, 2024 | 186.46 Mn |
| Mar 31, 2024 | 186.46 Mn |